Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy

NCT04480502 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT04480502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 9, 2020
Completion date
October 31, 2024
Enrollment
207 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

myxofibrosarcoma, undifferentiated pleomorphic sarcoma